During the 9th Microbiome Movement Summit Europe, held recently in Barcelona (Spain), Microbiomepost sat down with Maitrayee Chatterjee, Ph.D., Project Manager and Senior Scientist at InnoGI Technologies.

InnoGI Technologies has developed an innovative and non-invasive platform to mimic both the upper and lower gastrointestinal tract, offering precise and standardized models for microbiome research. 

Recently, InnoGI enhanced its Large Intestinal Model (TIM-2) by incorporating mucus, in collaboration with Bac3Gel, to better simulate the Mucus Associated Microbiome (MAM). This breakthrough allows for accurate and less invasive study of the microbiome, particularly its interaction with oral therapeutics.

In their research, InnoGI validated the mucus addition by showing the impact of metformin on the mucus associated microbiome (MAM), revealing how changes in the microbial community can be linked to therapeutic effects. Additionally, the combination of inulin and mucus was shown to have a synergistic effect, promoting the growth of probiotic bacteria such as Faecalibacterium and Akkermansia. 

With this advanced technology, InnoGI is now positioned to accurately predict the effects of oral drugs and explain underlying mechanism of food providing valuable insights for the future of microbiome-based therapies.